Short Interest in Revelation Biosciences, Inc. (NASDAQ:REVB) Declines By 43.6%

Revelation Biosciences, Inc. (NASDAQ:REVB) was the recipient of a large decline in short interest in April. As of April 15th, there was short interest totalling 18,500 shares, a decline of 43.6% from the March 31st total of 32,800 shares. Based on an average daily volume of 391,900 shares, the short-interest ratio is presently 0.0 days. Approximately 1.1% of the company’s shares are sold short.

Institutional Investors Weigh In On Revelation Biosciences

An institutional investor recently raised its position in Revelation Biosciences stock. Sabby Management LLC raised its stake in shares of Revelation Biosciences, Inc. (NASDAQ:REVB) by 14.2% in the third quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 403,233 shares of the company’s stock after buying an additional 50,000 shares during the period. Revelation Biosciences comprises about 0.2% of Sabby Management LLC’s investment portfolio, making the stock its 20th biggest holding. Sabby Management LLC owned 6.40% of Revelation Biosciences worth $278,000 as of its most recent filing with the Securities & Exchange Commission. 12.80% of the stock is currently owned by institutional investors.

Revelation Biosciences Price Performance

NASDAQ REVB traded up $0.04 on Friday, hitting $2.18. 45,621 shares of the stock were exchanged, compared to its average volume of 46,199. Revelation Biosciences has a 52-week low of $1.78 and a 52-week high of $39.00. The company has a market capitalization of $3.55 million, a price-to-earnings ratio of 0.07 and a beta of 0.11. The company’s 50-day moving average price is $2.67 and its two-hundred day moving average price is $10.70.

Revelation Biosciences (NASDAQ:REVB) last posted its quarterly earnings data on Friday, March 22nd. The company reported ($8.33) earnings per share for the quarter, topping the consensus estimate of ($10.94) by $2.61. Equities analysts predict that Revelation Biosciences will post -20.32 EPS for the current fiscal year.

Revelation Biosciences Company Profile

Revelation Biosciences, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of immune system therapeutics and diagnostics. The company engages in developing therapeutic product candidates, including REVTx-100, a potential therapy for the prevention and treatment of healthcare-associated bacterial infection resulting from surgery, severe burns, urinary tract infection, sepsis, and antibiotic resistance; REVTx-200, a potential intranasal therapy; and REVTx-300, a potential therapy for the treatment of chronic organ disease, including chronic kidney disease.